We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

106 hedge funds and large institutions have $130M invested in Lineage Cell Therapeutics in 2018 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 30 increasing their positions, 23 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

176% more call options, than puts

Call options by funds: $215K | Put options by funds: $78K

30% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 23

15% more capital invested

Capital invested by funds: $113M → $130M (+$17.1M)

0.45% more ownership

Funds ownership: 49.55% → 50% (+0.45%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1% less funds holding

Funds holding: 107 → 106 (-1)

9% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 11

Holders
106
Holders Change
-1
Holders Change %
-0.93%
% of All Funds
2.42%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
10
Increased
30
Reduced
23
Closed
11
Calls
$215K
Puts
$78K
Net Calls
+$137K
Net Calls Change
+$192K

Top Buyers

1
DWM
Destination Wealth Management
California
+$1.26M
2
BCM
Bridgeway Capital Management
Texas
+$458K
3
BlackRock
BlackRock
New York
+$446K
4
State Street
State Street
Massachusetts
+$214K
5
JG
Jefferies Group
New York
+$207K

Top Sellers

1
Axa
Axa
France
-$479K
2
Renaissance Technologies
Renaissance Technologies
New York
-$300K
3
TCIM
TIAA CREF Investment Management
New York
-$225K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$214K
5
DCM
DAFNA Capital Management
California
-$196K
Name Holding Trade Value Shares
Change 		Change in
Stake
AB
76
Amalgamated Bank
New York
$24K -$5.95K -2,834 -20%
ISB
77
Iowa State Bank
Iowa
$24K – – –
QPWM
78
Quadrant Private Wealth Management
Pennsylvania
$24K – – –
DWA
79
Douglass Winthrop Advisors
New York
$23K – – –
OCAM
80
Onex Canada Asset Management
Ontario, Canada
$23K – – –
PFA
81
Paradigm Financial Advisors
Missouri
$23K +$24K +11,430 New
SWP
82
Stratos Wealth Partners
Ohio
$22K +$22.1K +10,516 New
AIP
83
Ameritas Investment Partners
Nebraska
$14K – – –
RE
84
RBC Europe
United Kingdom
$13.4K – – –
Simplex Trading
85
Simplex Trading
Illinois
$12K -$26.6K -12,663 -68%
Canada Life
86
Canada Life
Manitoba, Canada
$12K – – –
LTFS
87
Ladenburg Thalmann Financial Services
Florida
$12K – – –
Zurich Cantonal Bank
88
Zurich Cantonal Bank
Switzerland
$12K – – –
Royal Bank of Canada
89
Royal Bank of Canada
Ontario, Canada
$11K -$4.86K -2,314 -30%
Bank of Montreal
90
Bank of Montreal
Ontario, Canada
$11K -$42 -20 -0.3%
CHP
91
Cable Hill Partners
Oregon
$11K – – –
FANJ
92
Financial Architects (New Jersey)
New Jersey
$9K – – –
BNP Paribas Financial Markets
93
BNP Paribas Financial Markets
France
$8.2K +$126 +60 +2%
AG
94
Advisor Group
Arizona
$8K – – –
FDCDDQ
95
Federation des caisses Desjardins du Quebec
Quebec, Canada
$7.05K – – –
RFA
96
Reilly Financial Advisors
California
$5K – – –
MAM
97
Meeder Asset Management
Ohio
$4K +$4.26K +2,029 New
TWA
98
TCI Wealth Advisors
Arizona
$3K – – –
SPIA
99
Steward Partners Investment Advisory
New York
$2K – – –
PA
100
Parallel Advisors
California
$1K – – –
1 2 3
4
5

LCTX Hedge Fund Activity: Q3 2018 in Review

106 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q3 2018, worth a combined $130M — up 15% from $113M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of LCTX and 10 opened new positions — a net loss of 1 holder — while 23 trimmed existing stakes and 30 added.

The largest buyer was Destination Wealth Management, opening a new position worth an estimated $1.26M. The largest seller was Axa, cutting an estimated $479K.

  • 106 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q3 2018, down from 107 in Q2 2018.
  • Funds reported $130M of Lineage Cell Therapeutics stock for Q3 2018, up 15% quarter-over-quarter.
  • 10 funds opened new Lineage Cell Therapeutics positions in Q3 2018 and 11 closed out, a net change of -1 holder.
  • The largest Lineage Cell Therapeutics buyer in Q3 2018 was Destination Wealth Management, an estimated $1.26M added.
  • The largest Lineage Cell Therapeutics seller in Q3 2018 was Axa, an estimated $479K sold.

Based on aggregated 13F filings for Q3 2018.